新股定价 | 派格生物医药每股定价15.6港元,公开发售获743.78倍认购,一手中签率8%

老虎资讯综合
27 May

派格生物医药-B 公布招股结果,香港公开发售接获743.78倍认购,一手(500股)中签率8%,认购10万股始获稳派一手。按回补机制,公开发售股份已增至964.2万股,占发售总数50%。国际配售录得1.13倍认购。发售价15.6港元,集资净额2.32亿港元。股份预期今日(27日)上市。

生物技术公司派格生物医药本次拟全球发售1,928.35万股,香港公开发售原占10%。基石投资者益泽康瑞旗下益泽康瑞医药(香港)获分配958.45万股,占发售後H股股本3.43%。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10